Vaxart (OTCMKTS:VXRT) Shares Pass Above 50 Day Moving Average – Here’s What Happened

Shares of Vaxart, Inc. (OTCMKTS:VXRT) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.66 and traded as high as $0.75. Vaxart shares last traded at $0.6910, with a volume of 494,037 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Vaxart to a “buy” rating in a report on Friday, January 23rd.

Vaxart Price Performance

The stock has a fifty day moving average of $0.66 and a 200 day moving average of $0.50. The firm has a market capitalization of $166.81 million, a P/E ratio of 11.52 and a beta of 1.31.

Vaxart (OTCMKTS:VXRT) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.32. The business had revenue of $104.24 million for the quarter, compared to analyst estimates of $35.95 million. Vaxart had a return on equity of 33.83% and a net margin of 6.88%. Equities analysts forecast that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Trading of Vaxart

Hedge funds have recently bought and sold shares of the business. Creative Planning bought a new stake in Vaxart during the second quarter worth $33,000. Raymond James Financial Inc. raised its stake in shares of Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the period. Marshall Wace LLP bought a new stake in shares of Vaxart in the second quarter valued at $794,000. Finally, Invesco Ltd. raised its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares during the period. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.